Medications for Liver Transplantation

10 results

  • Cyclosporine (cyclosporine)

    (Cyclosporine)
    Strides Pharma Science Limited
    Usage: Cyclosporine capsules (modified) are indicated for the prophylaxis of organ rejection in kidney, liver, and heart transplants, treatment of severe rheumatoid arthritis unresponsive to methotrexate, and severe plaque psoriasis in adults who have not adequately responded to systemic therapies or cannot tolerate them.

  • Cyclosporine (cyclosporine)

    (Cyclosporine)
    Teva Pharmaceuticals USA, Inc.
    Usage: Cyclosporine capsules, USP MODIFIED are indicated for organ rejection prophylaxis in kidney, liver, and heart transplants, treatment of severe active rheumatoid arthritis unresponsive to methotrexate, and severe plaque psoriasis in adults who failed previous systemic therapies or cannot tolerate them.

  • Gengraf (cyclosporine)

    (Cyclosporine)
    AbbVie Inc.
    Usage: Gengraf® (cyclosporine oral solution, USP [MODIFIED]) is indicated for the prevention of organ rejection in kidney, liver, and heart transplants, as well as for treating severe active rheumatoid arthritis unresponsive to methotrexate and severe plaque psoriasis in adults who have failed prior systemic therapies.

  • Mycophenolate mofetil (mycophenolate mofetil)

    (Mycophenolate Mofetil)
    Camber Pharmaceuticals, Inc.
    Usage: Mycophenolate mofetil capsules are indicated for preventing organ rejection in adult and pediatric patients (3 months and older) receiving allogeneic kidney, heart, or liver transplants, in combination with other immunosuppressive agents.

  • Mycophenolate mofetil (mycophenolate mofetil)

    (MYCOPHENOLATE MOFETIL)
    Advagen Pharma Limited
    Usage: Mycophenolate mofetil (MMF) is indicated for the prophylaxis of organ rejection in adult and pediatric patients (3 months and older) receiving allogeneic kidney, heart, or liver transplants, in combination with other immunosuppressants.

  • Mycophenolate mofetil (mycophenolate mofetil)

    (mycophenolate mofetil)
    American Health Packaging
    Usage: Mycophenolate mofetil (MMF) is indicated for the prevention of organ rejection in adult and pediatric patients (3 months and older) who have received allogeneic kidney, heart, or liver transplants, used in conjunction with other immunosuppressants.

  • Mycophenolate mofetil (mycophenolate mofetil)

    (Mycophenolate Mofetil)
    Amneal Pharmaceuticals NY LLC
    Usage: Mycophenolate mofetil for oral suspension is indicated for preventing organ rejection in adult and pediatric patients (3 months and older) undergoing allogeneic kidney, heart, or liver transplants, in conjunction with other immunosuppressive therapies.

  • Mycophenolate mofetil (mycophenolate mofetil)

    (Mycophenolate Mofetil)
    Lannett Company, Inc.
    Usage: Mycophenolate mofetil (MMF) is indicated for the prevention of organ rejection in adult and pediatric recipients aged 3 months and older undergoing allogeneic kidney, heart, or liver transplants, used in conjunction with other immunosuppressants.

  • Tacrolimus (tacrolimus)

    (Tacrolimus)
    REMEDYREPACK INC.
    Usage: Tacrolimus capsules are indicated for the prophylaxis of organ rejection in adult patients following allogeneic kidney, liver, or heart transplants, and in pediatric patients receiving allogeneic liver transplants, in combination with other immunosuppressants.

  • Tacrolimus (tacrolimus)

    (Tacrolimus)
    Major Pharmaceuticals
    Usage: Tacrolimus capsules are indicated for the prophylaxis of organ rejection in adult patients receiving allogeneic kidney, liver, or heart transplants, as well as in pediatric patients receiving allogeneic liver transplants, used in combination with other immunosuppressants.